- United Kingdom
- /
- Biotech
- /
- LSE:GNS
High Growth Tech Stocks in the United Kingdom
Reviewed by Simply Wall St
The United Kingdom's FTSE 100 index recently experienced a downturn, influenced by weak trade data from China and broader global economic concerns. Despite these challenges, identifying high-growth tech stocks in the UK market could offer potential opportunities for investors looking to navigate current market conditions.
Top 10 High Growth Tech Companies In The United Kingdom
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Gaming Realms | 11.57% | 22.07% | ★★★★★☆ |
STV Group | 13.15% | 46.78% | ★★★★★☆ |
Altitude Group | 23.46% | 27.56% | ★★★★★☆ |
YouGov | 14.29% | 29.79% | ★★★★★☆ |
Redcentric | 4.89% | 63.79% | ★★★★★☆ |
LungLife AI | 100.61% | 100.97% | ★★★★★☆ |
IQGeo Group | 11.49% | 63.61% | ★★★★★☆ |
Beeks Financial Cloud Group | 24.63% | 57.95% | ★★★★★☆ |
Vinanz | 113.60% | 125.86% | ★★★★★☆ |
Spirent Communications | 5.51% | 40.77% | ★★★★☆☆ |
Click here to see the full list of 46 stocks from our UK High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Genus (LSE:GNS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia and has a market cap of £1.26 billion.
Operations: Genus plc generates revenue primarily through its Genus ABS and Genus PIC segments, contributing £314.90 million and £352.50 million respectively. The company's operations span multiple regions including North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia.
Genus, operating in the biotech sector, reported a 4.1% annual revenue growth forecast, outpacing the UK market's 3.7%. However, net profit margins dropped to 1.2% from last year's 4.8%, impacted by a significant £47.8M one-off loss for the year ending June 30, 2024. Despite negative earnings growth of -76.3%, projections indicate a robust earnings increase of 39.4% per year over the next three years, suggesting potential recovery and expansion in its core segments. The company's recent full-year results showed sales at £668.8M compared to £689.7M previously and net income at £7.9M down from £33.3M last year; basic EPS fell to £0.12 from £0.508 prior period figures highlight challenges yet also underline resilience with consistent dividend affirmations (21.7 pence per share). Genus's R&D expenditure reflects its commitment to innovation within biotech advancements ensuring future competitiveness in this dynamic industry.
- Click here to discover the nuances of Genus with our detailed analytical health report.
Review our historical performance report to gain insights into Genus''s past performance.
Informa (LSE:INF)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Informa plc operates as an international events, digital services, and academic research company in the United Kingdom, Continental Europe, the United States, China, and internationally with a market cap of £11.17 billion.
Operations: Informa generates revenue through four primary segments: Informa Tech (£426.70 million), Informa Connect (£630.20 million), Informa Markets (£1.67 billion), and Taylor & Francis (£636.70 million). The company operates globally, providing services in events, digital solutions, and academic research across multiple regions including the UK, Europe, the US, and China.
Informa's revenue is projected to grow at 6.7% annually, outpacing the UK market's 3.7%. Despite a significant one-off loss of £213.5M impacting its recent financial results, earnings are forecasted to increase by 21.5% per year, indicating robust future prospects. The company has repurchased 41.67 million shares for £338.9M in the first half of 2024, demonstrating strong cash flow management and shareholder value focus amidst industry shifts towards digital and tech-driven solutions.
- Navigate through the intricacies of Informa with our comprehensive health report here.
Assess Informa's past performance with our detailed historical performance reports.
Sage Group (LSE:SGE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: The Sage Group plc, along with its subsidiaries, offers technology solutions and services for small and medium businesses across the United States, the United Kingdom, France, and internationally; it has a market cap of £10.36 billion.
Operations: Sage Group generates revenue primarily from its technology solutions and services for small and medium businesses, with significant contributions from North America (£1.01 billion) and Europe (£595 million). The company operates across the United States, the United Kingdom, France, and other international markets.
Sage Group's recent revenue growth of 9% in Q3 2024, reaching £585 million, underscores its robust performance driven by the Sage Business Cloud portfolio. The company's strategic partnership with VoPay enhances payroll functionalities for SMBs, addressing inefficiencies and manual processes. Notably, R&D expenses have been a focal point; with £120 million allocated in the past year, representing 8% of total revenue. Projected earnings growth at 15.1% annually outpaces the UK market's 14.3%, reflecting strong future prospects in software and AI advancements.
- Delve into the full analysis health report here for a deeper understanding of Sage Group.
Understand Sage Group's track record by examining our Past report.
Taking Advantage
- Take a closer look at our UK High Growth Tech and AI Stocks list of 46 companies by clicking here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Want To Explore Some Alternatives?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About LSE:GNS
Genus
Operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.
Good value with reasonable growth potential.